GSK pays $110 million upfront for exclusive rights to HUTCHMED’s dual-target cancer therapy HMPL-A830
GSK announced a partnership with Hong Kong-based HUTCHMED, paying $110 million upfront for exclusive global rights to develop HMPL-A830.
HMPL-A830 is an investigational antibody-targeted therapy conjugate that links an EGFR-directed monoclonal antibody with a small-molecule KRAS inhibitor, aiming for synergistic anti-tumor activity.
The collaboration will focus on colorectal, pancreatic and lung cancers, with GSK eligible for up to $1.185 billion in milestone payments and royalties on net sales.
GSK’s global head of Oncology R&D highlighted the dual KRAS-EGFR mechanism as a potential improvement over current standard-of-care treatments, reflecting the company’s strategy to source innovative assets from Asia.
This writeup was produced by pharmadog from original reporting by BioSpace.
Original headline: “GSK inks another Asia alliance, betting up to $1.3B for HUTCHMED’s cancer therapy”
read at BioSpace ↗
comments(0)
5-min edit window · permanent after that